Summary of Key Information:
Reporting Period: Quarter and Half Year Ended 30th September, 2026
Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 of SEBI LODR
Audit Opinion:
Clean - Limited Review Report issued by Statutory Auditors with no modifications
Key Financial Highlights [in lakhs]:
Consolidated Results:
For Quarter Ended 30th September 2026:
- Revenue from Operations: ₹31,913.58
- Total Income: ₹32,662.21
- Net Profit: ₹3,611.12
- EPS: ₹5.52
For Half Year Ended 30th September 2026:
- Revenue from Operations: ₹57,145.28
- Total Income: ₹58,171.67
- Net Profit: ₹6,900.67
- EPS: ₹10.72
Comparisons:
- Q2 FY26 Revenue growth of 110% YoY (₹31,913.58 vs ₹15,206.82 in Q2 FY25)
- H1 FY26 Revenue growth of 114% YoY (₹57,145.28 vs ₹26,735.03 in H1 FY25)
- Q2 FY26 Net Profit growth of 100% YoY (₹3,611.12 vs ₹1,802.12 in Q2 FY25)
- H1 FY26 Net Profit growth of 127% YoY (₹6,900.67 vs ₹3,044.20 in H1 FY25)
Standalone Results:
For Quarter Ended 30th September 2026:
- Revenue from Operations: ₹16,706.54
- Total Income: ₹17,007.35
- Net Profit: ₹1,555.69
- EPS: ₹2.37
For Half Year Ended 30th September 2026:
- Revenue from Operations: ₹34,903.69
- Total Income: ₹35,446.67
- Net Profit: ₹3,422.53
- EPS: ₹5.32
Segment-wise Performance:
Consolidated Segment Revenue [in lakhs]:
Q2 FY26:
- India: ₹24,575.48 (77% of total)
- Overseas: ₹7,338.10 (23% of total)
H1 FY26:
- India: ₹44,569.48 (78% of total)
- Overseas: ₹12,575.80 (22% of total)
Country-wise Export Revenue (H1 FY26) [in lakhs]:
- USA: ₹5,501.30
- United Kingdom: ₹997.51
- Brazil: ₹1,611.67
- France: ₹1,593.03
- Canada: ₹1,611.67
- 11 other countries contributing remaining exports
Corporate Actions:
QIP Completion (June 2026):
- Allotted 33,01,886 equity shares of face value ₹10 each
- Issue price: ₹1,060 per share (including premium of ₹1,050)
- Total proceeds: ₹34,999.99 lakhs (net of expenses: ₹34,179.48 lakhs)
- Utilization: ₹3,000.00 lakhs for debt repayment, ₹23,525.75 lakhs for subsidiary working capital, ₹7,653.73 lakhs for general corporate purposes
- Fully utilized as of reporting date
IPO Fund Utilization:
- Total IPO proceeds (net): ₹31,111.66 lakhs
- ₹23,575.66 lakhs invested in subsidiary KRN HVAC Products for new manufacturing facility
- ₹7,536.00 lakhs for general corporate purposes
- Fully utilized as of reporting date
Other Significant Information:
- Company manufactures fin and tube type heat exchangers for HVAC&R industry using non-ferrous metals (copper and aluminium)
- Product range includes condenser coils, evaporator units, header/copper parts, fluid and steam coils, sheet metal parts
- Subsidiaries included in consolidation: KRN HVAC Products Private Limited and Thermotech Research Laboratory Private Limited
- Subsidiaries contributed revenue of ₹23,984.39 lakhs (Q2) and ₹40,517.14 lakhs (H1)
Balance Sheet Highlights [Consolidated, in lakhs]:
As at 30th September 2026:
- Total Assets: ₹1,37,979.89
- Equity Share Capital: ₹6,545.85
- Other Equity: ₹91,880.12
- Cash and Cash Equivalents: ₹14,133.52
- Total Debt: ₹15,317.83 (Short-term: ₹15,302.76, Long-term: ₹15.07)
Comparison with 31st March 2026:
- Total Assets increased by ₹44,798.29 lakhs (48% growth)
- Equity increased by ₹41,026.49 lakhs (71% growth)
- Cash and equivalents increased by ₹13,134.73 lakhs